Immunovant, Inc. IMVT
Set alert
28.41 USD -0.76 -2.61%
At close
28.01 -0.40 -1.41%
Pre-market · Nov 3, 4:04 AM ET
28.38 Day range 29.64
21.43 52-week range 45.42
- YTD
- +11.76%
- 1 year
- +15.11%
- Open
- 29.32
- Prev close
- 29.17
- Mkt cap
- 5.87B
- Vol
- 1.27M
- Avg vol
- 1.36M
- EPS
- -2.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 28.38
- High
- 29.64
- Forward P/E
- -10.33
- Beta
- 0.94
- Short ratio
- 10.91
- Inst. own
- 54.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 34.56
- 200-d avg
- 32.04
- 1y target
- 48.88
3M chart
Events in this range
- Aug 4, 2026Rating: JP Morgan · Overweight → Overweight
- Aug 6, 2026Earnings: -0.75; estimate -0.6289; surprise -19.26%
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Sep 23, 2026 | 1 month ago |
| RSI: Oversold | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 3 months ago |
Analyst view
Consensus: buy
Buy
Price target (mean) 48.88 +72.0% upside
Now 28.41
- Target (low)
- 30.00
- Target (mean)
- 48.88
- Target (high)
- 66.00
Ratings (0m) 17 13 buy · 4 hold · 0 sell
- Strong buy2
- Buy11
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 17
- 1 month ago 17
- 2 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.72212 | -0.75751 – -0.69886 | -0.6482 | -11.4% | 0 | 0.0% | 3 |
| Next quarter | -0.67107 | -0.76971 – -0.53349 | -0.5373 | -24.9% | 0 | 0.0% | 3 |
| Current year | -2.84 | -3.05 – -2.52 | -2.47 | -15.1% | 0 | 0.0% | 5 |
| Next year | -2.75 | -3.21 – -2.38 | -2.84 | +3.2% | 36.81M | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 4, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jun 30, 2026 | Citigroup | Maintained | Buy | Buy |
| May 26, 2026 | Guggenheim | Maintained | Buy | Buy |
| May 22, 2026 | Truist Securities | Maintained | Hold | Hold |
| May 21, 2026 | B of A Securities | Maintained | Buy | Buy |
| May 21, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 15, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Feb 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 9, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jan 8, 2026 | Truist Securities | Maintained | Hold | Hold |
| Jan 6, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Dec 15, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 14, 2025 | Truist Securities | Initiated | — | Hold |
| Sep 30, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 4, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 12, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 12, 2025 | B of A Securities | Maintained | Buy | Buy |
| Jul 28, 2025 | UBS | Maintained | Neutral | Neutral |
| Apr 22, 2025 | UBS | Downgrade | Buy | Neutral |
| Mar 20, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Mar 20, 2025 | B of A Securities | Maintained | Buy | Buy |
| Mar 19, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 10, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 10, 2025 | Guggenheim | Maintained | Buy | Buy |
| Feb 10, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 7, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 15, 2025 | B of A Securities | Maintained | Buy | Buy |
| Jan 3, 2025 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| Dec 19, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |